GlassScriptPhysician profile
Matthew Alan Roberts
NPI 1700878139
$3,148.19
in general payments reported to CMS, 2019-2025
34 companies · $490 in 2025
The $490 reported for 2025 was more than what 80% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $329 · 2020: $332 · 2021: $664 · 2022: $575 · 2023: $405 · 2024: $353 · 2025: $490.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,248.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,247.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $807.16 | 2019-2024 | Lo Loestrin Fe, Ubrelvy, Qulipta |
| Avion Pharmaceuticals | $389.43 | 2019-2022 | |
| Sumitomo Pharma America, INC. | $251.68 | 2023-2025 | Myfembree, Gemtesa |
| Mayne Pharma Commercial LLC | $207.62 | 2021-2025 | |
| Sage Therapeutics, LLC | $183.34 | 2024-2025 | Zurzuvae |
| Astellas Pharma US INC | $167.41 | 2023-2025 | Veozah |
| Pfizer INC. | $115.43 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $99.31 | 2021-2025 | |
| Myovant Sciences INC. | $96.38 | 2021-2022 | |
| Exeltis, USA INC. | $74.54 | 2020-2021 | |
| Novo Nordisk INC | $72.12 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Coopersurgical, INC. | $68.20 | 2019-2022 | |
| Therapeuticsmd, INC. | $57.84 | 2019-2020 | |
| Shield Therapeutics INC | $52.38 | 2023-2024 | Accrufer |
| Kowa Pharmaceuticals America, INC. | $51.83 | 2023 | Seglentis |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scynexis, INC. | $50.09 | 2022 | |
| Baxter Healthcare | $43.61 | 2025 | Seprafilm |
| Organon LLC | $41.26 | 2022-2024 | |
| Biohaven Pharmaceutical Holding Company LTD. | $40.60 | 2022 | |
| Supernus Pharmaceuticals, INC. | $38.92 | 2025 | Qelbree |
| Mylan Pharmaceuticals INC. | $33.66 | 2020-2021 | |
| Roche Diagnostics Corporation | $22.71 | 2021 | |
| Janssen Pharmaceuticals, INC | $20.84 | 2022 | |
| Vertex Pharmaceuticals Incorporated | $19.67 | 2025 | |
| Lilly USA, LLC | $18.46 | 2025 | Zepbound |
| Medtronic, INC. | $16.61 | 2025 | Interstim |
| Abbott Laboratories | $15.11 | 2024 | Proclaim |
| Ethicon US, LLC | $14.07 | 2024 | Surgicel Nu-Knit, Ethicon, Stratafix |
| Smith+Nephew, INC. | $13.94 | 2025 | Pico |
| Merck Sharp & Dohme LLC | $13.59 | 2019 | |
| Exact Sciences Corporation | $12.95 | 2023 | Cologuard Collection Kit |
| Allergan, INC. | $12.78 | 2019 | |
| Evofem Biosciences, INC. | $12.36 | 2020 | |
| Amag Pharmaceuticals, INC. | $12.29 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Roberts listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.